We're thrilled to have @juanpabloarab join our team to push our alcohol-related liver disease research to the next level. Learn more about him at bit.ly/4d9Z5Ww #livertwitter
Arun J. Sanyal
427 posts
Arun J. Sanyal
@ArunJSanyalVCU
The views expressed here do not necessarily reflect those of VCU, its medical school or the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health.
- Honored to have my contributions to the field of #hepatology recognized and to be included among the top cited 🌐 Clarivate Reveals World's Influential Researchers in Highly Cited Researchers 2023 List #livertwitter prn.to/3QYYM8P
- Congratulations to my colleague @jasmohanbajaj, whose oral presentation at #ACG2024 was deemed one of the best at the conference. The presentation on #HE was given the @AmCollegeGastro Outstanding Research Award in the liver category. bit.ly/48uWZzw
- What an incredible #EASLCongress in Milan! So much to take in, so much to discuss about #MASH. We will continue at @AASLDtweets #TLM in San Diego. #livertwitter @EASLnews
- I'll be with @juanpabloarab at the @AASLD session this afternoon on "Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol-Associated Liver Disease, and MetALD: Beyond the Nomenclature." Check out our session. #livertwitter #TLM24
- Initial ESSENCE data we shared today at #TLM24 demonstrate that semaglutide 2.4mg slows MASH progression and reverses existing liver damage. The ESSENCE data may represent key findings for patients in the treatment of #MASH. #livertwitter @aasldtweets @novonordisk @phil_newsome7
- Exciting news in @HEPJournal: MASEF Score, based on combination of serum-based metabolomics and clinical data and developed by @OWLMetabolomics, can accurately identify #MASLD with ≥F2 fibrosis (at-risk MASH) #livertwitter @NoureddinMD @RMayo_OWL bit.ly/47yPB4j
- Thrilled to learn of the election of @jasmohanbajaj to the Association of American Physicians! See the entire list of honorees at aap-online.org #livertwitter
- 🆕REVIEW: Digital pathology and artificial intelligence in non-alcoholic steatohepatitis ➡️Current status and future directions. Read it here👉 bit.ly/3Qlsnbh via @JHepatology #LiverTwitter
- A major milestone for our #liver patients and for the field. As an investigator working on MASH, I congratulate @MadrigalPharma & the communities of my colleagues and patients who participated in the treatment trials to make approved therapy for #MASH a reality. #livertwitter#BREAKING It is a big day for the Liver Community! Madrigal is proud to announce the first and only @US_FDA-approved therapy in NASH/MASH. Learn more here: bit.ly/3Pmyqwr #FDAApproval #NASH
00:00 - October is ... #LiverAwarenessMonth! The liver is a central metabolic organ that coordinates the healthy functioning of the 🫀, 🧠, and kidneys. Visit @VCU_Liver for #liver facts and figures this month, and don’t forget to #Get2KnowYourLiver. #OctoberIs4Livers #LiverTwitter
- Great 📰 2 share in liver disease diagnosis! Our latest @FNIH_Org NIMBLE results in @NatureMedicine. Noninvasive blood tests could revolutionize #NASH / #MASH diagnosis, care & reduce the need for biopsies. go.nature.com/3ZdLyYA #LiverTwitter #ParisNASHMeeting @VCU @VCUHealth
- Via @JHepatology November issue: Efficacy, tolerability and pharmacokinetics of survodutide, a GLP1/GCGR agonist, in #cirrhosis. #OpenAccess here👉 bit.ly/3Ba0tex #LiverTwitter
- New Review in @NatureMedicine: Our call for inclusion of patients with #MASLD and measurement of liver outcomes in cardio-kidney-metabolic trials, when data suggest benefits and safety. go.nature.com/4evnXcm @FaiezZANNAD @JavedButler1 #livertwitter
